Option Therapeutics Inc. (OPTN)
| Market Cap | 55.00M |
| Revenue (ttm) | n/a |
| Net Income | -1.28M |
| EPS | -0.26 |
| Shares Out | 5.00M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 860,961 |
| Open | 9.67 |
| Previous Close | 9.71 |
| Day's Range | 9.48 - 9.72 |
| 52-Week Range | 4.82 - 20.03 |
| Beta | -0.89 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 14, 2025 |
About OPTN
Option Therapeutics is a clinical-stage company developing innovative drug therapies to treat debilitating and life-threatening liver disease through our investigational drug candidate BIV201 (continuous infusion terlipressin). BIV201 has been granted both Food and Drug Administration (“FDA”) Fast Track designation status and FDA Orphan Drug Status, which designations provide certain advantages in the review process, but do not guarantee a faster development process, regulatory review or approval as compared to the conventional FDA review and ... [Read more]
Financial Performance
Financial StatementsNews
BioVie liver disease carve-out Option Therapeutics files and sets terms for a $25 million IPO
Option Therapeutics, a Phase 2 liver disease biotech spun out of BioVie, filed on Monday with the SEC to raise up to $25 million in an initial public offering.
Option Therapeutics IPO Registration Document (S-1)
Option Therapeutics has filed to go public with an IPO on the NYSE American